Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

This review aims to provide a systemic analysis of the in vivo, as well as subcellular, fate of
polymeric micelles (PMs), starting from the entry of PMs into the body. Few PMs are able to …

In recent years, much progress has been motivated in stimuli-responsive nanocarriers,
which could response to the intrinsic physicochemical and pathological factors in diseased …

Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several
conjugates successfully translated into clinical practice. The conjugation of therapeutic …

Over the last three decades, polymeric micelles have emerged as a highly promising drug
delivery platform for therapeutic compounds. Particularly, poorly soluble small molecules …

Polymeric micelles are demonstrating high potential as nanomedicines capable of
controlling the distribution and function of loaded bioactive agents in the body, effectively …

Although conventional chemotherapy has been successful to some extent, the main
drawbacks of chemotherapy are its poor bioavailability, high-dose requirements, adverse …

Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum
application in cancer therapy. To overcome this challenge, an ideal treatment strategy would …

Current cancer nanomedicines can only mitigate adverse effects but fail to enhance
therapeutic efficacies of anticancer drugs. Rational design of next‐generation cancer …

The development of biodegradable polymers represents a revolution in medicine spanning
over 50 years and leading to significant biotechnological advancements in drug delivery …